2010;7:906 11. S7.9.1.1-25. Laksman ZW, Hamilton RM, Chockalingam P, et al. Mutation loca- tion effect on severity of phenotype during exercise testing in type 1 long-QT syndrome: impact of transmembrane and C-loop loca- tion. J Cardiovasc Electrophysiol. 2013;24:1015 20. S7.9.1.1-26. Moltedo JM, Kim JJ, Friedman RA, et al. Use of a cardioselective beta-blocker for pediatric patients with prolonged QT syndrome. Pediatr Cardiol. 2011;32:63 6. S7.9.1.1-27. Sy RW, van der Werf C, Chattha IS, et al. Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. Circulation. 2011;124:2187 94. S7.9.1.1-28. Villain E, Denjoy I, Lupoglazoff JM, et al. Low incidence of cardiac events with beta-blocking therapy in children with long QT syn- drome. Eur Heart J. 2004;25:1405 11. S7.9.1.1-29. Viskin S, Postema PG, Bhuiyan ZA, et al. The response of the QT interval to the brief tachycardia provoked by standing: a bed- side test for diagnosing long QT syndrome. J Am Coll Cardiol. 2010;55:1955 61. S7.9.1.1-30. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292:1341 4. S7.9.1.1-31. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol. 2011;57:51 9. S7.9.1.1-32. Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 1997;96:2149 54. S7.9.1.1-33. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syn- drome. Pharmacol Rev. 2010;62:760 81. S7.9.1.1-34. Zhang C, Kutyifa V, Moss AJ, et al. Long-QT syndrome and therapy for attention deficit/hyperactivity disorder. J Cardiovasc Electrophysiol. 2015;26:1039 44. S7.9.1.1-35. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866 74. 